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INITIAL EXPERIENCE WITH USING FRAMELESS IMAGE-GUIDED 
RADIOSURGERY FOR THE TREATMENT OF BRAIN METASTASES
Z. Liepa, K. Auslands*, D. Apskalne, R. Ozols
Riga East Clinical University Hospital, Riga LV-1038, Latvia
Aim: Recent technologic advances have led to the development of frameless radiosurgery. We report our initial results using frame-
less image-guided radiosurgery for the management of brain metastases. Methods: Over a 2-year period, 16 patients harboring 
28 lesions were treated in our institution. 12 of 16 patients were treated in a single fraction, but 4 patients were treated using 
fractioned stereotactic radiotherapy in 3–5 fractions. The maximum target diameter, as determined by T1 — weighted contrast — 
enhanced magnetic resonance imaging were < 4 cm in all patients. 8 patients (50%) received WBRT (3 Gy in 10 fractions to a to-
tal dose of 30 Gy) prior to stereotactic radiosurgery, and were treated with SRS for either lesion progression or new lesions. The 
total treatment volume for each patient was the sum of the treatment volumes for all treated metastases. The median total treatment 
volume was 18.63 cm3 (range 1,85–47.03 cm3). Results: Median overall survival time of entire group were 10 months (95% con-
fidence interval 7.470–12.530 months). Of the 3 (11.11%) lesions that showed complete response, all were associated with breast 
cancer. Partial response was seen in 8 (29.62%) cases. Stable disease was seen in 13 (48.14%) cases, but 3 (11.11%) cases showed 
progression of disease. Conclusion: Further studies are needed to to match the treatment results with other available modalities 
to optimize and individualize care of patients with brain metastases.
Key Words: brain metastases, frameless image-guided radiosurgery.
Brain metastases represent an important ca�se 
of morbidity and mortality and may occ�r in �����% 
of patients with cancer [�]. The incidence of brain 
metastases has increased over time as a conseq�ence 
of the increase in overall s�rvival for many types 
of cancer and the improved detection by magnetic 
resonance imaging �MRI�.
C�rrent treatment options for brain metastases 
incl�de s�rgical resection� stereotactic radios�rgery� 
whole brain radiation therapy �WBRT�� hypofractio­
nated stereotactic radiotherapy� and more recently 
chemotherapy aģents with some degree of central 
nervo�s system activity [�� �].
In the last �� years radios�rgery in addition to s�r­
gery and whole­brain radiotherapy� by virt�e of its 
noninvasive nat�re and high lesion control rates� has 
emerged as one of key options for patients with brain 
metastases [�].
Radios�rgery has been demonstrated to res�lt 
in s�perior local control compared with WBRT alone. 
Frame­based methods of radios�rgery �sing either 
LINAC or gamma �nit devices are well established.
Frameless image g�idance as applied to radio­
s�rgery describes a method whereby high­resol�tion 
imaging is obtained at the time of treatment for patient 
positioning p�rposes and implies that patient immobi­
lization is not obtained with rigid skeletal fixation� b�t 
rather with the noninvasive �se of a mask.
Frameless image­g�ided methods in the setting 
of single­fraction radios�rgery have as their primary 
advantage the potential for improved patient comfort. 
As there no sedation or anesthesia is �sed� no vital 
monitoring is req�ired. Frame­based radios�rgery 
methods have a long history� and the reliability of these 
methods is not in disp�te. In contrast� since image­ 
g�ided methods are relatively new� few reports are 
available detailing clinical res�lts for common applica­
tions of this technology.
Since ����� Novalis frameless image­g�ided 
radios�rgery �IGRS� system is available in Riga East 
Clinical University Hospital and we report o�r initial 
res�lts �sing frameless IGRS for the management 
of brain metastases.
MATERIAL AND METHODS
The records of patients with brain metastases who 
were treated with IGRS in Riga East Clinical Univer­
sity Hospital of one or more lesions between �an�ary� 
���� and March� ���� were retrospectively reviewed. 
Approval of Riga East Clinical University Hospital Medi­
cal ethics committee was obtained.
Over a �­year period� �6 patients harboring �7 le­
sions were treated in o�r instit�tion. Patients were of­
fered treatment for metastatic disease of the brain 
with one or more metastases and a Karnofsky Perfor­
mance Scale score of 7� or greater at time of initial 
presentation to o�r clinic. In the patient sample were 
represented � male and �� female patients with mean 
age �9.�� years �min = ��� max = 7�� SE = ���9��. The 
majority �n = �� of patients had brest cancer metas­
tases �Table ��. �� patients demonstrated metachro­
nos development of metastasis� whereas the others 
revealed synchrono�s development. There were 
�� cases that presented with one metastasis� � cases 
with two metastases� � case with five metastases and 
� case with six metastases.
�� of �6 patients were treated in a single fraction� 
b�t � patients were treated �sing fractioned stereotactic 
radiotherapy in ��� fractions �Table ��. The maxim�m 
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target diameter� as determined by T�­weighted con­
trast — enhanced MRI were < � cm in all patients . Eight 
patients ���%� received WBRT �� Gy in �� fractions 
to a total dose of �� Gy� prior to stereotactic radio­
s�rgery� and were treated with SRS for either lesion 
progression or new lesions. Other eight patients did not 
have WBRT d�ring the st�dy period.
Table 1. Distribution of tumor types in 16 patients
Tumor type Number of patients Number of metastases
breast 8 13
melanoma 2 3
lung 3 7
ovary & cervix 2 3
non-Hodkin’s lymphoma 1 1
Table 2. Treatment modalities used
Treatment mo-
dality
Number 
of patients Target (volume range)
Marginal dose 
(range)
IGRS 9 25.12 cm3 (2.03–47.03) 18 Gy (15–24)
WBRT + IGRS 3 8.15 cm3 (1.85–15.79) 18 Gy (18–20)
WBRT + fSRT 4 22.36 cm3 (6.80–39.47) 15.35Gy 
in 3–5 fractions
The treatment isodose vol�me for each metastasis 
was calc�lated �sing GammaPlan software. The total 
treatment vol�me for each patient was the s�m of the 
treatment vol�mes for all treated metastases. The 
median total treatment vol�me was ���6� cm� �range 
������7.�� cm��.
Patients were followed �p with contrast­enhanced 
MR imaging at 6�� weeks following SRS treatment 
and then every � months �ntil the end period of data 
collection or patient demise.
Response criteria to treatment �sed were defined 
on the basis of MRI scans as follows: complete re­
sponse �CR�� as complete resol�tion of the enhancing 
lesion� partial response �PR�� >��% red�ction in the 
size of the lesion� stable disease �SD�� no change 
in the dimension of the lesion� or < ��% red�ction� and 
progression of disease �PD�� > ��% increase in the 
size of the lesion.
S�rvival was calc�lated from the date of radios�r­
gery to the last follow­�p eval�ation or death.
Radiosurgery technique. Patients were immo­
bilized d�ring comp�ted tomography �CT� and treat­
ments �sing the BrainLAB non­invasiv stereotactic 
immobilization mask system.
MRI scan was available for each patient to help 
to define the target vol�me. The t�mor was delineated 
�sing MRI images and after that co­registration be­
tween CT and MRI images was done in order to transfer 
target vol�me to CT images that are �sed for dose cal­
c�lations. The clinical target vol�me �CTV� was defined 
as the �nion of GTVs delineated on MRI images as well 
as on CT­scans. No margin was added for s�bclinical 
extension. The margin for the planning target vol�me 
�PTV� was � mm in all directions added to the CTV. 
Stereotactic radios�rgery �SRS� was planned with 
EclipseTM �Varian Medical Systems INC, USA� treatment 
planning system �TPS� �sing vol�metric intensity mod�­
lated dose delivery by RapidArcTM �Varian Medical Sys-
tems INC, USA� or intensity mod�lated radiation therapy 
�IMRT� with 7�9 intensity mod�lated treatment fields 
�Fig. ��. Treatment plan was normalized to ��% isodose 
line and normalized ���% isodose line encompassed 
the PTV. Linear accelerator NovalisTxTM eq�ipped with 
a high­definition m�ltileaf collimator �MLC ���HD� was 
�sed for SRS delivery. All plans were delivered �sing 
photon energy 6 MV and dose rate of ���� monitor 
�nits �MU� per min�te. For patient position correction� 
ExacTrac® 6D �� transversal directions and � rotations� 
Image­G�ided Radiotherapy �IGRT� System �BrainLAB 
GMBH, Munich, Germany� was �sed.
Fig. 1. CT images with isodose lines showing a treatment plan 
of brain metastasis
Quality assurance procedures. All treatment 
plans were verified from dosimetric point of view via 
complex verification proced�re� which incl�ded dose 
plane meas�rements and point dose meas�rements 
in phantom and Winston — L�tz test. Dose plane 
meas�rements were performed �sing Gafchromic 
EBT � films end eval�ated performing gamma index 
method. Generally res�lts were considered accept­
able if more than 9�% of eval�ated points passed 
gamma criteria � mm/�%. Point dose meas�rements 
were performed �sing pinpoint �D �PTW, Freiburg, 
Germany� ionization chamber. The tolerance level 
for the point dose meas�rements was set to �%. The 
treatment �nit was considered to be appropriate for 
treatment deli very if isocentre sphere� as meas�red 
via Winston — L�tz test� did not exceeded � mm.
Statistical methods. S�rvival probability was 
estimated with the Kaplan — Meier method. Log­rank 
test was �sed to test wether there was a difference 
between the s�rvival time of different gro�ps of treat­
ment. Statistical analysis was performed �sing the 
Statistical Package for the Social Sciences �SPSS�.
RESULTS
Median overall s�rvival time of entire gro�p were 
�� months �9�% CI 7.�7����.��� months� �Fig. ��.
Overall s�rvival depending on the type of therapy 
�p = �.���: WBRT+FSRS �� patients� — median overall 
s�rvival were �� months �9�% CI �.������.76� months�; 
WBRT+SRS �� patients� — median overall s�rvival were 
7 months �9�% confidence interval �.�99���.��� months�; 
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SRS �9 patients� — median overall s�rvival were �� months 
�9�% confidence interval �.������.��� months�.
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Fig. 2. Median overall s�rvival time for entire gro�p — �� months 
�9�% CI 7��7������ months�
R e g a rd i n g  o v e ra l l  s � r v i v a l  d e p e n d i n g 
on the type of t�mor �p = �.�7�: breast cancer �� pa­
tients� — ��.�7� months �9�% CI �.�����.7� months�; 
l�ng cancer �� patients� — ��.�� months �9�% 
CI �����6.�67 months�; melanoma �� patients� — 
9 months �9�% CI ����.6� months�. 
� ���.��%� patients developed new metastases 
following radios�rgery treatment.
Of the � ���.��%� lesions that showed CR� all 
were associated with breast cancer. PR was seen 
in � ��9.6�%� cases �Fig. �� ��� and were associated 
with breast cancer in � cases and � each with ovary� 
l�ng and non­Hodkin’s lymphoma cancers. SD was 
seen in �� ���.��%� cases. These patients incl�ded 
� with breast cancer� � with l�ng cancer� � with 
melanoma� � with cervix� and � with ovary cancers. 
� ���.��%� cases showed PD — � melanoma cancer� 
and � l�ng cancer patients.
At the time of data analysis� 9 of the �6 patients 
in o�r st�dy gro�p were still alive� 7 had died d�ring 
the reporting period.
D�ring follow �p� brain radionecrosis was regis­
tered in one patient with melanoma �� month after 
SRS. Diagnosis was s�spected by MRI �at the mo­
ment SPECT and PET examinations are not available 
in Latvia� and confirmed by histological examination 
after operation which was done beca�se of s�spected 
progression of the disease with mass efect.
Fig. 3. Patient 6�­year­old woman with posterior fossa lesion 
secondary to metastatic breast cancer
Fig. 4. Follow­�p MR image obtained 6 month after treatment 
showing s�bstantial red�ction of metastasis vol�me �PR to treat­
ment�
DISCUSSION
Brain metastases are a common complica­
tion of cancer� with an overall incidence estimated 
to be ���� per ��� ��� [�]. Radios�rgery has emerged 
as a key method of providing definitive local control for 
brain metastases in addition to s�rgery and WBRT [6].
The �se of frame­based skeletal immobilization 
for stereotactic proced�res has a long history dating 
back to the �9��s with the introd�ction of stereotactic 
systems designed by Leksell� Talaraich� Reichert and 
M�ndinger� Todd and Wells� and others [7].
Stereotactic radios�rgery permits the deli­
very of a single high dose of radiation to a target 
of ����� cm of maxim�m diameter by �sing gamma­
knife �m�ltiple cobalt so�rces� or linear accelerator 
�Linac� thro�gh a stereotactic device. The rapid dose 
fall­off of SRS minimizes the risk of damage to the 
s�rro�nding normal nervo�s tiss�e. St�dies have 
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demonstrated that the application acc�racy of these 
devices is on the order of � mm [�].
In patients with newly diagnosed brain metasta­
ses a decrease of symptoms� a local t�mor control 
�defined as shrinkage or arrest of growth� at � year 
of ���9�% and a median s�rvival of 6��� months have 
been reported [9� ��]. Metastases from radioresistant 
t�mors� s�ch as melanoma� renal cell carcinoma and 
colon cancer� respond to SRS as well as do metastases 
from radiosensitive t�mors. Radios�rgery allows the 
treatment of brain metastases in almost any location. 
The type of radios�rgical proced�re� gamma­knife 
or Linac based� does not have an impact on the res�lt 
[��]. S�rvival following radios�rgery is comparable 
with that achieved with s�rgery [9� ��].
The reliable immobilization and target localization 
acc�racy of invasive frame­based radios�rgery have 
established the techniq�e as a gold standart� b�t 
it is associated with significant disadvantages. Many 
patients consider head frame placement to be a tra�­
matic experience. Use of the stereotactic frame does 
have some disadvantages incl�ding the proced�ral 
discomfort for most patients� with awake placement 
being typically performed with local anesthetic only. 
Frame­placement involves risk of bleeding and infec­
tion� and req�ires pre­medication. F�rthermore� the 
care of patients wearing head frames creates a clinical 
reso�rce b�rden on the day of care� req�iring dedi­
cated n�rsing and physician s�pport. Frame­based 
treatment also req�ires treatment planning to be com­
pleted following frame placement on the day of treat­
ment� making it less feasible to incorporate advanced 
dose planning techniq�es s�ch as IMRT. Head frames 
may also slip� compromising treatment acc�racy� and 
potentially res�lting in inj�ry to the patient [��]. 
The disadvantages associated with invasive head 
frames become of greater concern as more patients 
receive radios�rgery� and more are being treated 
on m�ltiple occasions. It becomes important to opti­
mize patient comfort and treatment efficiency. 
The �se of frameless radios�rgery is evolving and 
early reports s�ggest similar o�tcomes to patients 
treated with frame­based radios�rgery [�����]. Also� 
high control rates are seen for small lesions in which 
spatial precision in dose delivery is critical [�6]. How­
ever� the optimal management of brain metastases 
remains controversial [�7].
From o�r data d�e to small n�mber of patients 
in treatment gro�ps its hard to make definite decisions� 
b�t o�r treatment res�lts are compareable to other 
available st�dies.
However� s�rgery contin�es to play an essen­
tial role in the management of lesions complicated 
by mass effect or after fail�re of less­invasive treat­
ment methods [��].
In concl�sion� we present o�r early data and experi­
ence to control of brain metastases �sing frameless 
IGRS method. F�rther st�dies are needed to match 
the treatment res�lts with other available modalities 
to optimize and individ�alize care of patients with brain 
metastases.
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